Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Transvaginal ultrasonography and hysterosonography to monitor endometrial effects in tamoxifen-treated patients
1Department of Obstetrics and Gynecology, University of Genova, Italy
2Medical Oncology, S. Croce General Hospital, Cuneo, Italy
3Medical Oncology Division, National Institute for Cancer Research, Genova, Italy
*Corresponding Author(s): M. Valenzano E-mail:
Purpose of investigation: Our purpose was to evaluate if, during tamoxifen treatment, hysterosonography may increase diagnostic accuracy when compared with transvaginal ultrasonography and to identify, when and in how many cases, further biopsies may be avoided.
Methods: We performed transvaginal utrasound in 310 asymptomatic women under tamoxifen treatment, using 8 mm endometrial thickness as the cut-off. One hundred and seven patients with an endometrium thicker than 8 mm were enrolled for hysterosonography. Parameters to be evaluated by transvaginal ultrasound and hysterosonography were thickness and structural features of the endometrium. It was possible to compare ultrasound examinations with histopathological findings obtained by biopsy in 83 patients.
Results: Globally only ten patients from the study cohort had true endometrial pathology. Based on structural features of the endometrium, we found a global accuracy of 95.6%, with 2.8% false negatives and 4.1% false positives.
Conclusion: Hysterosonography can increase diagnostic accuracy during tamoxifen treatment and may allow further invasive investigations to be avoided in patients with suggestive hysterosonographic features.
Tamoxifen; Endometrium; Transvaginal ultrasound; Hysterosonography
M. Valenzano,G. F. Bertelli,S. Costantini,A. Corticelli,L. Del Mastro,R. Paoletti,O. Garrone,R. Rissone. Transvaginal ultrasonography and hysterosonography to monitor endometrial effects in tamoxifen-treated patients. European Journal of Gynaecological Oncology. 2001. 22(6);441-444.
[1] Rutqvist L. E., Johanson H., Signomklao T., Johansson U., Fornander T., Wilking N.: "Adiuvant tamoxifen therapy for early stage breast cancer and second primary malignancy". J. Natl Cancer Inst., 1995, 87, 645.
[2] Ismail S. M.: "Pathology of endometrium treated with tamoxifen" J. Clin. Pathol., 1994, 47, 827.
[3] Neven P., De Muylder X., van Belle Y., Vanderyck G., De Muylder E.: "Tamoxifen and the uterus and endometrium". Lancet, 1989i, 375.
[4] Lahti E., Blanco G., Kauppila A.: "Endometrial change in postmenopausal breast cancer patients receiving tamoxifen". Obstet Gynecol., 1993, 81, 660.
[5] Cohen I.,A ltaras M. M.,S hapira J., Tepper R., Beyth Y.: "Postmenopausal tamoxifen treatment and endometrial pathology". Obstet. Gynecol. Surv., 1994, 49, 823.
[6] FleisherA., Kalemeris G.C .,M achin J.E.,E ntman S.S .,James E Jr.: "Sonographic depiction of normal and abnormal endometrium with histopathologic correlation". J. Ultrasound Med., 1986, 5, 445.
[7] Nasri M. N.,C oast G. J.: "Correlation of ultrasound findings and endometrial histopathology in postmenopausal women". B1: J. Obstet. Gynaecol., 1989, 96, 1333.
[8] Parson A. K., Lense J. J.: "Sonohysterography for endometrial abnormalities: preliminary results". J. Clin. Ultrasound , 1993, 21, 87.
[9] Valenzano M.,C ostantini S.,C ucuccio S.,D ugnani M.C .,Paoleltl R., Ragni N.: "Use of hysterosonography in women with abnormal postmenopausal bleeding". Eur. J. Gynaec. Oneal., 1999, 20, 217
[10] Schwartz L.B., Snyder J., Horan C., Porges R. F., Nachtigall L E., Goldstein S. R.: "The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen". Ultrasound Obstet. Gynecol., 1998, 11, 48.
Top